Skip to main content
NATR
NASDAQ Life Sciences

CFO Resigns; SVP, Chief Accounting Officer Appointed Interim Principal Financial Officer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Food & Beverage Stocks · Consumer
Sentiment info
Negative
Importance info
7
Price
$24.23
Mkt Cap
$426.081M
52W Low
$12.973
52W High
$28.14
52W Position info
87% above low
Off High info
14% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

NATR sits 87% above its 52-week low of $12.973.

Summary

Nature's Sunshine Products announced the resignation of its Chief Financial Officer, L. Shane Jones, and the appointment of Jonathan D. Lanoy, SVP and Chief Accounting Officer, as Interim Principal Financial Officer.


Key Events · Executive and Board Changes · NATR

  • Chief Financial Officer Resigns

    L. Shane Jones notified the company of his resignation as Chief Financial Officer and Principal Financial Officer, effective June 5, 2026. The company stated his resignation was not due to any disagreement with financial reporting or accounting policies.

  • Interim Principal Financial Officer Appointed

    Jonathan D. Lanoy, currently the Senior Vice President, Chief Accounting Officer, and Principal Accounting Officer, was appointed Interim Principal Financial Officer, effective May 8, 2026. Mr. Lanoy has been with the company since 2008.

  • Interim Officer's Compensation Details

    Mr. Lanoy's employment agreement provides for an annual base salary of $301,551 and a target annual bonus of 50% of his base salary, along with severance benefits under certain termination conditions.


Analysis · NATR · Life Sciences

The departure of a Chief Financial Officer introduces uncertainty regarding financial leadership and strategy. While the company stated the resignation was not due to disagreements and an internal, experienced executive has been appointed as interim, the search for a permanent CFO will be an ongoing process that investors will monitor for stability and future direction.

At the time of this filing, NATR was trading at $24.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $426.1M. The 52-week trading range was $12.97 to $28.14. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NATR - Latest Insights

NATR
May 11, 2026, 8:53 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $24.23
Real-time Price: $19.78 info
Change: -$4.45 (-18%) info
Market Cap: $347.829M info
NATR
May 07, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.83
Real-time Price: $19.78 info
Change: -$8.05 (-29%) info
Market Cap: $347.829M info
NATR
May 07, 2026, 5:13 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $27.83
Real-time Price: $19.78 info
Change: -$8.05 (-29%) info
Market Cap: $347.829M info
NATR
May 07, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $24.42
Real-time Price: $19.78 info
Change: -$4.64 (-19%) info
Market Cap: $347.829M info
NATR
Apr 20, 2026, 5:28 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $27.07
Real-time Price: $19.78 info
Change: -$7.29 (-27%) info
Market Cap: $347.829M info